JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37
Oct 8, 2025 · On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $33 from $37 while keeping an Overweight rating on the shares.
Immunovant, Inc. (IMVT) - Yahoo Finance
Find the latest Immunovant, Inc. (IMVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cathie Wood snatches $8 million of battered tech stock
Sep 8, 2024 · Cathie Wood, chief of Ark Investment Management, is buying more shares of one of her favorite positions, seeking to take advantage of a recent decline. Investors and analysts diverge in …
IMVT Interactive Stock Chart | Immunovant, Inc. Stock - Yahoo Finance
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Immunovant, Inc. (IMVT) Latest Stock News & Headlines - Yahoo Finance
Get the latest Immunovant, Inc. (IMVT) stock news and headlines to help you in your trading and investing decisions.
Immunovant Provides Corporate Updates and Reports Financial Results …
Feb 6, 2026 · IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data ...
Immunovant Provides Corporate Updates and Reports Financial Results …
Aug 11, 2025 · Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025All ...
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates …
Feb 7, 2026 · Earnings update and pipeline progress Immunovant (IMVT) shares moved after a cluster of company updates, including fully enrolled pivotal rheumatoid arthritis trials for IMVT-1402, plans to …
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 ...
Mar 4, 2026 · Immunovant, Inc. (NASDAQ:IMVT) ranks among the most shorted stocks to buy according to analysts. On February 6, Immunovant, Inc. (NASDAQ:IMVT) released its Q3 2025 results, …
Immunovant Announces Pricing of $550 Million Common Stock …
Dec 11, 2025 · Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage …